CoChat
Sign Up
Cited by 196Inflammatory Bowel DiseaseHealth Systems, Economic Evaluations, Quality of LifeMusculoskeletal pain and rehabilitation

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn’s disease

Reilly, Margaret C., Gerlier, Laetitia, Brabant, Yves, Brown, Martin·2008·Clinical Therapeutics
DOI 10.1016/j.clinthera.2008.02.016
Open this paper in CoChat — free account

Abstract

Background Crohn's disease (CD) is a chronic inflammatory bowel disease usually diagnosed in early adult life and characterized by unpredictable flares and debilitating symptoms such as diarrhea, abdominal pain, and fever, which can interfere with a patient's ability to work and perform daily activities.Objective The aim of this study was to assess the validity, reliability, and responsiveness of the Work Productivity and Activity Impairment questionnaire in CD (WPAI:CD).Methods The WPAI:CD was tested in CD patients enrolled in a 26-week randomized clinical trial of cer-tolizumab pegol versus placebo. Discriminative validity of WPAI:CD absenteeism, presenteeism(reduced on-the-job effectiveness), overall work productivity loss (absenteeism + presenteeism), and activity impairment scores was assessed relative to 5 measures of disease severity and health status: CD Activity Index (CDAI), Short Form-36 physical component summary (PCS) and mental health component summary (MCS) scores, Inflammatory Bowel Disease Questionnaire (IBDQ), and the 5-dimensional EuroQoL health-related quality-of-life visual analog scale (EQ-VAS). Responsiveness was assessed by comparing changes in WPAI:CD scores from baseline to week 26 for patients in remission (CDAI <150 points) versus no remission. Standardized Response Means (SRMs) were calculated to evaluate the magnitude of the changes.Results A total of 662 patients (mean [range] age, 37.4 [18-77] years; male, 288 [43.5%]; white, 629 [95.0%]) were enrolled in the study. Patients with CD of the worst severity (CDAI > median) showed significantly higher impairment in work (+10.5%) and activities (+10.4%) versus patients with "best health" (no problems) (both, P < or = 0.001). Patients with "worst" IBDQ, PCS, MCS, and EQ-VAS scores also showed significantly higher impairments in work (IBDQ, VAS -24.2%; PCS, -24.1%; MCS, -15.9%; EQ-VAS, -16.5%) and activities (IBDQ, -23.3%; PCS, -21.8%; MCS, -16.5%; EQ-VAS, -17.2%) versus "best" scores (all, P < 0.05). There were significant differences between WPAI:CD impairment scores for patients in remission versus patients failing to achieve remission (P < 0.05). SRMs were small (ie, <0.5) in the nonre-mission group, and moderate to large (ie, >0.5) for patients in remission.Conclusions The discriminative validity, reliability, and responsiveness of the WPAI:CD were demonstrated. The WPAI:CD may be useful for evaluating drug impact on CD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.clinthera.2008.02.016

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Research works printed but not linked: 4

  1. Ekbom, 1998, Cost to society of Crohn's disease, Res Clin Forums, 20, 33
  2. Joshua-Gotlib, 2004, Evaluation of the burden of illness in patients with mild to moderate Crohn disease, Drug Benefit Trends, 16, 600
  3. Wahlqvist, 2003, Resolution of upper gastrointestinal symptoms associated with chronic non-steroidal anti-inflammatory drug therapy has a positive impact on patient-reported productivity, Gastroenterology, 124, A107
  4. 2000, EQ-5D: A measure of heath-related quality of life developed by the EuroQol Group: User guide, EuroQol Group

Cited by

Sorted by citations

Items 101–196 of 196

Related

See all

Metadata

Authors
Reilly, M. C., Gerlier, L., Brabant, Y., & Brown, M.
ORCID
Gerlier, Laetitia
Venue
Clinical Therapeutics
Publisher
Elsevier BV
Published
2008-02
Volume
30
Issue
2
Pages
393-404
ISSN
0149-2918 (ISSN-L)
DOI
10.1016/j.clinthera.2008.02.016
OpenAlex
W2107743584
Cited by
196
References
41
Citations by year
2026: 7 · 2025: 9 · 2024: 19 · 2023: 16 · 2022: 15 · 2021: 13 · 2020: 14 · 2019: 14 · 2018: 11 · 2017: 3 · 2016: 10 · 2015: 7 · 2014: 13 · 2013: 5 · 2012: 5
FWCI
6.46
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Clinical Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
Keywords
Crohn's disease, Work Productivity and Activity Impairment, labor productivity, activity impairment, absenteeism, presenteeism, disease severity, health-related quality of life, remission, questionnaire validity, responsiveness, inflammatory bowel disease, patient-reported outcomes, standardized response mean, CDAI, IBDQ, EQ-VAS, SF-36
MeSH terms
Absenteeism, Certolizumab Pegol, Activities of Daily Living, Adolescent, Adult, Aged, Crohn Disease, Female, Gastrointestinal Agents, Humans, Immunoglobulin Fab Fragments, Male, Middle Aged, Polyethylene Glycols, Predictive Value of Tests, Quality of Life, Surveys and Questionnaires, Severity of Illness Index, Time Factors, Reproducibility of Results, Treatment Outcome, Cost of Illness, Sick Leave, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review